Drugs that contain Fentanyl Citrate
1. List of Fentora drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8092832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Dec, 2024
(1 year, 10 months from now) | |
| US8119158 | CEPHALON | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
Dec, 2024
(1 year, 10 months from now) | |
| US7862833 | CEPHALON | Effervescent oral opiate dosage forms and methods of administering opiates |
Jun, 2028
(5 years from now) | |
| US7862832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Jun, 2028
(5 years from now) | |
Market Authorisation Date: 25 September, 2006
Treatment: NA
Dosage: TABLET;BUCCAL, SUBLINGUAL
2. List of Lazanda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9814705 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(11 months from now) | |
| US9078814 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(11 months from now) | |
| US8889176 | BTCP PHARMA | Method of managing or treating pain |
Jan, 2024
(11 months from now) | |
| US8216604 | BTCP PHARMA | Method of managing or treating pain |
Oct, 2024
(1 year, 7 months from now) | |
| US9731869 | BTCP PHARMA | Container |
Jan, 2032
(8 years from now) | |
Market Authorisation Date: 30 June, 2011
Treatment: Management of breakthrough pain in patients with cancer
Dosage: SPRAY, METERED;NASAL
3. List of Onsolis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597288 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
Market Authorisation Date: 16 July, 2009
Treatment: Management of breakthrough pain in patients with cancer
Dosage: FILM;BUCCAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic